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To investigate a possible role for human rhinovirus C in 
respiratory exacerbations of children with cystic ﬁ  brosis, we 
conducted microbiologic testing on respiratory specimens 
from 103 such patients in São Paulo, Brazil, during 2006–
2007. A signiﬁ  cant association was found between the pres-
ence of human rhinovirus C and respiratory exacerbations.
C
ystic ﬁ  brosis (CF) is an autosomal inherited disease 
characterized by recurrent and chronic respiratory in-
fections that ultimately lead to the need for a lung transplant 
early in life or to death (1). The role of bacterial infections 
in CF is well established, and most treatments focus on 
eradication or suppression of bacterial infections (mainly 
those caused by Pseudomonas aeruginosa) (1).
Respiratory viruses such as respiratory syncytial virus 
(RSV) and inﬂ  uenza also seem to cause early damage or 
increase the risk for respiratory exacerbations (2,3) in these 
patients. However, the role of newly described respiratory 
viruses is not well known. Infection of these patients with 
human rhinovirus (HRV), a member of the family Picor-
naviridae, has been described. Although some studies have 
suggested a substantial pathogenic role for these viruses 
(3), controversy still exists (4).
Recently a new clade of human rhinovirus, named 
rhinovirus C (5), was identiﬁ  ed through molecular meth-
ods. This new clade has been found throughout the world 
(6), and some studies have attributed severe respiratory 
infections in children to this agent (7,8). We investigated 
whether this agent played a role in the respiratory exacerba-
tions of children and adolescents with CF who attended the 
Instituto da Crinaça, Hospital das Clínicas da Faculdade de 
Medicina da Universidade de São Paulo.
The Study
A total of 103 CF patients (49 girls, 54 boys; median 
age 8.9 years; age range 3.8 months–17.8 years) were en-
rolled in the study from September 6, 2006 through Sep-
tember 4, 2007. Nasopharyngeal aspirates or nasal mucus 
specimens for viral investigation, as well as sputum or 
oropharyngeal samples for microbiology culture, were col-
lected during scheduled visits or unscheduled visits on 408 
occasions, with a median ± SD of 4 ± 1.74 visits per patient 
(range 1–9 visits).
Clinical and lung function data were obtained at all 
visits. Exacerbation of respiratory disease was deﬁ  ned as 
the presence of >2 of the following signs or symptoms: 
fever, increase in the amount of secretion or cough inten-
sity, change in sputum’s color, worsening of dyspnea, loss 
of appetite, a decrease of forced expiratory volume in 1 s 
>10%, and weight loss.
Total nucleic acids were extracted from nasopharyn-
geal samples by using a QIAmp Viral RNA Mini Kit (QIA-
GEN, Hamburg, Germany), according to manufacturer’s 
instructions. Reverse transcription was conducted with 
High Capacity cDNA Archive Kit (Applied Biosystems, 
Foster City, CA, USA) by using 20 μL of the previously 
extracted RNA. Respiratory viruses were identiﬁ  ed by in-
dividual reverse transcription–PCRs or PCRs selective for 
RSV; inﬂ  uenza viruses A and B; human parainﬂ  uenza vi-
ruses 1, 2, and 3; human coronavirus; human metapneu-
movirus; adenovirus; human bocavirus; picornavirus; and 
the β-actin gene (9). For picornavirus, we used the primer 
pair OL26–OL27, which include a portion of the 5′ non-
coding region (NCR) common to all picornaviruses, in the 
same conditions previously described (10). After sequence 
ampliﬁ  cation, products were examined by capillary elec-
trophoresis in an automated DNA sequencer (MegaBace, 
General Electric Healthcare–Amersham Biosciences, Lit-
tle Chalfont, UK), and results were visualized through the 
MegaBace FragmentProﬁ  ler software, which discriminates 
fragment sizes and ﬂ  uorescent intensities.
Samples in which picornavirus cDNA had been identi-
ﬁ  ed were submitted to a TaqMan-based real-time PCR pro-
tocol (11) to identify HRV and enterovirus. Only samples 
in which rhinovirus had been identiﬁ  ed by real-time PCR 
were submitted to 5′ ΝCR sequencing with an ABI 377 
automated sequencer (Applied Biosystems), and results 
were submitted to the GenBank database, accession nos. 
GU933027–GU933118. Sequencing of the 5′ NCR region 
has been shown to accurately discriminate among subtypes 
of rhinovirus, including genotypes C and A2 (12). All se-
quencing chromatograms obtained were edited manually to 
obtain contiguous fragments (contigs), by using Sequence 
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Navigator software (Applied Biosystems). All sequences 
were screened at the National Center for Biotechnology 
Information website by using the Basic Local Alignment 
Search Tool (BLAST) (http://blast.ncbi.nlm.nih.gov/Blast.
cgi). HRV genotype was conﬁ  rmed by phylogenetic analy-
sis as described below. Sequences generated and a set of ref-
erence strains representative of HRV genotypes, available 
in the GenBank database, were aligned by using ClustalW 
(www.ebi.ac.uk/Tools/clustalw2). Minor manual adjust-
ments were made to improve the alignment with BioEdit 
software (www.mbio.ncsu.edu/BioEdit/BioEdit.html). The 
sequence of echovirus 11 was used as the outgroup. Phylo-
genetic analysis was performed with PAUP* version 4b10 
(http://paup.csit.fsu.edu). Neighbor-joining and maximum-
likelihood trees were constructed on the basis of appropri-
ate nucleotide substitution models determined by Modeltest 
v3.7 (University of Vigo, Vigo, Spain). Bootstrapping was 
assessed by using 1,000 replicates. Trees were visualized 
by using the TreeView program (www.taxonomy.zoology.
gla.ac.uk/rod/treeview.html).
To account for correlations among samples from the 
same patient, we used binomial generalized linear models 
to identify the virologic variables associated with the main 
endpoints (respiratory exacerbation and hospital admis-
sion). Results were presented as odds ratios (ORs) and 95% 
conﬁ  dence intervals.
At least 1 respiratory virus was identiﬁ   ed in 203 
(49.8%) of 408 samples; rhinovirus was the main identiﬁ  ed 
agent (139 samples, 34.1%). The results of virus identiﬁ  -
cation, in relation to clinical status, are shown in Table 1. 
Co-infections were found in only 26 samples (6.4%); rhi-
novirus was the most frequent agent.
Sequencing was performed in 93 of 139 samples that 
were positive for rhinovirus and showed a predominance 
of genotype A (36 samples; 38.7%) (Figure 1). Rhinovi-
rus subtypes A2 and C were identiﬁ  ed in 14 samples each. 
Isolates in 3 samples were identiﬁ  ed as HRV87, coxsacki-
evirus, and echovirus. Therefore, 5 isolates were entero-
viruses, which indicates that the TaqMan–based real-time 
PCR platform misidentiﬁ  ed them. Sequencing was not suc-
cessful in 1 sample. A maximum-likelihood phylogenetic 
tree of our samples and reference HRV sequences was con-
structed (Figure 2).
Patients were examined during acute exacerbation of 
respiratory disease on 142 occasions, and patients required 
hospital admission on 31 occasions. The identiﬁ  cation of 
respiratory viruses was not associated with pulmonary ex-
acerbations. Because rhinovirus was the main agent identi-
ﬁ  ed among stable patients, we veriﬁ  ed the effects of re-
spiratory viruses, excluding rhinovirus from the analysis. 
A signiﬁ  cant association with respiratory exacerbation was 
found (OR 1.195, p = 0.010) (Table 2).
In contrast, when looking at rhinovirus subtypes, we 
noticed that identiﬁ  cation of rhinovirus subtypes A2 or C 
was also signiﬁ  cantly associated with respiratory exacerba-
tions (OR 1.213) (Table 2). Identiﬁ  cation of inﬂ  uenza A 
was the only variable associated with an increase in the risk 
for hospital admission (OR 1.988, 95% conﬁ  dence interval 
1.238–3.194, p = 0.004).
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Table 1. Respiratory viruses and clinical status of 103 children with cystic fibrosis , Brazil, 2006–2007 
Virus
No. samples collected during 
routine visits, n = 266 
No. samples collected during 
respiratory exacerbations, n = 142  Total no. (%) samples 
Rhinovirus 91 48 139 (34.1) 
Enterovirus 13 11 24 (5.9) 
Human bocavirus  14 9 23 (5.6) 
Human coronavirus  13 6 19 (4.7) 
Respiratory syncytial virus  7 8 15 (3.7) 
Influenza A  1 3 4 (1.0) 
Human metapneumovirus  1 2 3 (0.7) 
Influenza B  1 0 1 (0.2) 
Parainfluenza 1  0 1 1 (0.2) 
Parainfluenza 2  0 1 1 (0.2) 
Parainfluenza 3  0 1 1 (0.2) 
Adenovirus 0 1 1 (0.2) 
36
23
14
14
5 Rhinovirus A
Rhinovirus B
Rhinovirus A2
Rhinovirus C
Enterovirus
Figure 1. Results of 5′ noncoding region sequencing of 93 samples 
with identiﬁ   cation of human rhinovirus by real-time reverse 
transcription–PCR, obtained from samples from 103 children with 
cystic ﬁ  brosis, Brazil, 2006–2007. Conclusions
These new HRV genotypes were initially described 
in samples from patients with inﬂ  uenza-like illnesses (13). 
Recently, evidence has been increasing for the involvement 
of HRV-C in severe respiratory conditions such as bron-
chiolitis in infants (7) and in exacerbation of asthma (14). 
However, these studies that attempted to clarify the patho-
genicity of these new species did not include control groups 
or nonsymptomatic persons.
In the study reported here, we obtained samples from 
patients during routine visits and exacerbations, which en-
abled us to identify a distinct role of different HRV sub-
types. Our ﬁ  ndings, however, cannot be extrapolated to 
infants with CF, which were underrepresented in our study. 
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Figure 2. Representative maximum-likelihood 
phylogenetic tree of a partial 5′ noncoding 
region  of human rhinovirus generated 
with general time reversible substitution   
model, including gamma distribution shape 
parameter. Reference human rhinovirus 
(HRV) genotypes were obtained from the 
GenBank database. Echovirus 11 was deﬁ  ned 
as the outgroup. Virus isolates obtained in 
this study are indicated by boldface and 
are labeled VFC. Bootstrap values >70% in 
the key branches are depicted. Scale bar 
indicates nucleotide substitutions per site.
Table 2. Virologic test results and respiratory exacerbation outcome for 103 children with cystic fibrosis, Brazil, 2006–2007* 
Virus OR (95% CI)  p value 
Any respiratory virus  1.063 (0.979–1.154)  0.144 
Rhinovirus 1.020 (0.931–1.117)  0.666 
Any respiratory virus except rhinoviruses  1.195 (1.043–1.369)  0.010 
Rhinovirus A2 or C (excluding samples not sequenced)  1.213 (1.024–1.436)  0.025 
*Estimates from binomial, generalized linear models. OR, odds ratio; CI, confidence interval. Rhinovirus C and Cystic Fibrosis
These infants may be at greater risk of HRV-C respiratory 
infections as they are for with RSV infections (2). 
Previous studies of respiratory virus infections in CF 
patients provided conﬂ  icting results on the potential effect 
of rhinovirus. Smyth et al. (15), who evaluated respiratory 
exacerbations in CF patients, identiﬁ  ed rhinovirus as the 
leading agent, with exacerbations following a more benign 
course but resulting in greater use of intravenous antimicro-
bial drugs (15). Olesen et al. (4) studied 75 CF patients for 
1 year and used PCR to investigate the presence of 7 differ-
ent viruses in sputum or laryngeal aspirates. The group re-
ported that viral infections did not reduce lung function or 
increase respiratory symptoms. Rhinovirus was by far the 
leading agent identiﬁ  ed throughout their study (4). A more 
recent study by Wat et al. (3), in which they used real-time 
nucleic acid sequence–based ampliﬁ  cation in conjunction 
with molecular markers to investigate the presence of 9 
respiratory viruses in children with CF, described an as-
sociation of viral infections with respiratory exacerbations, 
particularly those caused by inﬂ  uenza A, inﬂ  uenza B, and 
rhinovirus (3).
We report infections by the novel rhinovirus subtypes 
A2 and C in CF patients. A signiﬁ  cant association was 
found between the presence of these agents and respiratory 
exacerbations. Our ﬁ  ndings indicate the need for further in-
vestigation of HRV-C in CF patients.
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